Carmichael Hill & Associates’s GoodRx Holdings GDRX Stock Holding History

Carmichael Hill & Associates’s Portfolio GDRX Stock Details GDRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-100	Closed	-$6K	–	743
2020 Q3	$6K	Buy	+100	New	+$5.29K	﹤0.01%	576

Other funds holding GDRX

FPM

Francisco Partners Management San Francisco, California $292M AUM 34.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SLG

Silver Lake Group Menlo Park, California $3.68B AUM 7.22% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Tiger Global Management New York $22.8B AUM 30.07% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

LSCM

Light Street Capital Management Palo Alto, California $534M AUM 59.08% 1-Year Est. Return

ZCI

Zevenbergen Capital Investments Edmonds, Washington $4.38B AUM 56.68% 1-Year Est. Return

Carmichael Hill & Associates's GDRX Position: Q4 2020 in Review

Carmichael Hill & Associates sold out of GoodRx Holdings (GDRX) in Q4 2020, closing a stake of 100 shares — an estimated $6K sold.

Carmichael Hill & Associates first reported a position in GDRX in Q3 2020 and held it in 1 quarter. The position peaked at $6K in Q3 2020. 192 funds tracked by Wall St. Rank hold GDRX as of Q4 2020.

Carmichael Hill & Associates reported no remaining GoodRx Holdings position as of Q4 2020 after selling out during the quarter.
Carmichael Hill & Associates sold 100 GoodRx Holdings shares in Q4 2020, an estimated $6K.
Carmichael Hill & Associates first reported a position in GoodRx Holdings in Q3 2020 and held it in 1 quarter.
Carmichael Hill & Associates's GoodRx Holdings position peaked at $6K in Q3 2020.
192 funds tracked by Wall St. Rank held GoodRx Holdings as of Q4 2020.

Based on Carmichael Hill & Associates's 13F filing for Q4 2020, filed 27 Jan 2021.